Encaleret

BridgeBio's Attruby (acoramidis) has demonstrated remarkable early demand, with 430 prescriptions written by 248 unique healthcare providers since FDA approval.

BridgeBio's acoramidis shows positive Phase 3 results for ATTR-CM, with an FDA PDUFA date set for November 29, 2024, and potential $500M milestone payment upon approval.

A post-hoc analysis of BridgeBio Pharma's Phase 3 ATTRibute-CM study highlights acoramidis' potential in treating transthyretin cardiomyopathy.

BridgeBio Pharma has completed enrollment for its Phase 3 FORTIFY study evaluating BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9).

The FDA granted Breakthrough Therapy Designation to BridgeBio's infigratinib for treating children with achondroplasia, a genetic bone growth disorder.